{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:34:49Z","timestamp":1780144489410,"version":"3.54.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hepatology Rep"],"DOI":"10.1007\/s11901-023-00600-z","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:14:33Z","timestamp":1677172473000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications"],"prefix":"10.1007","volume":"22","author":[{"given":"Mohamed A.","family":"Elfeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7888-1165","authenticated-orcid":false,"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"600_CR1","unstructured":"Singal AK, Kamath PS. Variceal hemorrhage. In: Sahni P, Nundy S, editors. New Delhi, India, 2012:1."},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2468-1253(18)30232-2","volume":"3","author":"X Qi","year":"2018","unstructured":"Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3:708\u201319.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"600_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","volume":"75","author":"C Engelmann","year":"2021","unstructured":"Engelmann C, Claria J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75(Suppl 1):S49\u201366.","journal-title":"J Hepatol"},{"key":"600_CR4","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3:100316.","journal-title":"JHEP Rep"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","volume":"2","author":"D Lebrec","year":"1980","unstructured":"Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol\u2013a medical treatment for portal hypertension? Lancet. 1980;2:180\u20132.","journal-title":"Lancet"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/cld.1182","volume":"19","author":"A Rabiee","year":"2022","unstructured":"Rabiee A, Garcia-Tsao G, Tapper EB. Nonselective beta-blockers in portal hypertension: why, when, and how? Clin Liver Dis (Hoboken). 2022;19:118\u201323.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00281-020-00829-6","volume":"42","author":"D Sharma","year":"2020","unstructured":"Sharma D, Farrar JD. Adrenergic regulation of immune cell function and inflammation. Semin Immunopathol. 2020;42:709\u201317.","journal-title":"Semin Immunopathol"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0950-3528(97)90038-5","volume":"11","author":"G D'Amico","year":"1997","unstructured":"D\u2019Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol. 1997;11:243\u201356.","journal-title":"Baillieres Clin Gastroenterol"},{"issue":"1246\u20131275","key":"600_CR9","first-page":"e1243","volume":"42","author":"Z Miao","year":"2020","unstructured":"Miao Z, Lu J, Yan J, Lu L, Ye B, Gu M. Comparison of therapies for secondary prophylaxis of esophageal variceal bleeding in cirrhosis: a network meta-analysis of randomized controlled trials. Clin Ther. 2020;42(1246\u20131275):e1243.","journal-title":"Clin Ther"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2036.2010.04418.x","volume":"32","author":"LL Gluud","year":"2010","unstructured":"Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther. 2010;32:859\u201371.","journal-title":"Aliment Pharmacol Ther"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"\u2022\u2022 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374. Recent Baveno VII conference recommendations for the management of portal hypertension.","journal-title":"J Hepatol"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/apt.16901","volume":"55","author":"PDJ Dunne","year":"2022","unstructured":"Dunne PDJ, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead J, Smith LA, et al. Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Aliment Pharmacol Ther. 2022;55:1581\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"600_CR13","doi-asserted-by":"crossref","unstructured":"Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, Hofer B, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol 2022;S1542-3565(22)00642-5.","DOI":"10.1016\/j.cgh.2022.06.007"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/hep.30220","volume":"69","author":"M Sharma","year":"2019","unstructured":"Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, Simonetto DA. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatol. 2019;69:1657\u201375.","journal-title":"Hepatol"},{"key":"600_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatol. 2017;65:310\u201335.","journal-title":"Hepatol"},{"key":"600_CR16","doi-asserted-by":"publisher","first-page":"e000290","DOI":"10.1136\/bmjgast-2019-000290","volume":"6","author":"D Tripathi","year":"2019","unstructured":"Tripathi D, Hayes PC, Richardson P, Rowe I, Ferguson J, Devine P, Mathers J, et al. Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). BMJ Open Gastroenterol. 2019;6:e000290.","journal-title":"BMJ Open Gastroenterol"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1053\/gast.1997.v113.pm9352866","volume":"113","author":"M Angelico","year":"1997","unstructured":"Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterol. 1997;113:1632\u20139.","journal-title":"Gastroenterol"},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"\u2022 Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, Banares R, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597\u2013608. The seminal randomized controlled trial to demonstrate the benefit of carvedilol in preventing hepatic decompensation and improving patient survival in patients with clinically significant portal hypertension.","journal-title":"Lancet"},{"key":"600_CR19","doi-asserted-by":"crossref","unstructured":"Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 2022;\u00a077(4):1014\u201325.","DOI":"10.1016\/j.jhep.2022.05.021"},{"key":"600_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/MCG.0000000000001431","volume":"55","author":"GN Kalambokis","year":"2021","unstructured":"Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, et al. Conversion of propranolol to carvedilol improves renal perfusion and outcome in patients with cirrhosis and ascites. J Clin Gastroenterol. 2021;55:721\u20139.","journal-title":"J Clin Gastroenterol"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","volume":"6","author":"J Bosch","year":"2009","unstructured":"Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573\u201382.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1002\/hep.32033","volume":"74","author":"W Bai","year":"2021","unstructured":"Bai W, Al-Karaghouli M, Stach J, Sung S, Matheson GJ, Abraldes JG. Test-retest reliability and consistency of HVPG and impact on trial design: a study in 289 patients from 20 randomized controlled trials. Hepatol. 2021;74:3301\u201315.","journal-title":"Hepatol"},{"key":"600_CR23","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/hep.32159","volume":"74","author":"G Garcia-Tsao","year":"2021","unstructured":"Garcia-Tsao G. Can we rely on changes in HVPG in patients with cirrhosis? Hepatol. 2021;74:2945\u20137.","journal-title":"Hepatol"},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","volume":"326","author":"AK Singal","year":"2021","unstructured":"\u2022 Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326:165\u201376. A review and update on diagnosis and management of alcohol-associated liver disease including non-invasive assessment in high-risk patients.","journal-title":"JAMA"},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1478-3231.2010.02286.x","volume":"30","author":"R Cubillas","year":"2010","unstructured":"Cubillas R, Rockey DC. Portal hypertensive gastropathy: a review. Liver Int. 2010;30:1094\u2013102.","journal-title":"Liver Int"},{"key":"600_CR26","first-page":"1244","volume":"84","author":"SK Sarin","year":"1989","unstructured":"Sarin SK, Kumar A. Gastric varices: profile, classification, and management. Am J Gastroenterol. 1989;84:1244\u20139.","journal-title":"Am J Gastroenterol"},{"key":"600_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/lt.26383","volume":"28","author":"KT Osman","year":"2022","unstructured":"Osman KT, Nayfeh T, Abdelfattah AM, Alabdallah K, Hasan B, Firwana M, Alabaji H, et al. Secondary prophylaxis of gastric variceal bleeding: a systematic review and network meta-analysis. Liver Transpl. 2022;28:945\u201358.","journal-title":"Liver Transpl"},{"key":"600_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatol. 2003;37:902\u20138.","journal-title":"Hepatol"},{"key":"600_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2007.01191.x","volume":"102","author":"A Albillos","year":"2007","unstructured":"Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, Molinero LM. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol. 2007;102:1116\u201326.","journal-title":"Am J Gastroenterol"},{"key":"600_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MEG.0000000000000812","volume":"29","author":"AJ Kerbert","year":"2017","unstructured":"Kerbert AJ, Chiang FW, van der Werf M, Stijnen T, Slingerland H, Verspaget HW, van Hoek B, et al. Hemodynamic response to primary prophylactic therapy with nonselective beta-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:380\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"600_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/hep.23689","volume":"51","author":"J Bosch","year":"2010","unstructured":"Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatol. 2010;51:2214\u20138.","journal-title":"Hepatol"},{"key":"600_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","volume":"150","author":"FA McAlister","year":"2009","unstructured":"McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784\u201394.","journal-title":"Ann Intern Med"},{"key":"600_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.03.048","volume":"73","author":"E Alvarado-Tapias","year":"2020","unstructured":"Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montanes R, Pavel O, Cuyas B, Graupera I, et al. Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020;73:829\u201341.","journal-title":"J Hepatol"},{"key":"600_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cld.2019.06.004","volume":"23","author":"C Bunchorntavakul","year":"2019","unstructured":"Bunchorntavakul C, Reddy KR. Pharmacologic management of portal hypertension. Clin Liver Dis. 2019;23:713\u201336.","journal-title":"Clin Liver Dis"},{"key":"600_CR35","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jceh.2022.03.002","volume":"12","author":"AV Kulkarni","year":"2022","unstructured":"Kulkarni AV, Rabiee A, Mohanty A. Management of portal hypertension. J Clin Exp Hepatol. 2022;12:1184\u201399.","journal-title":"J Clin Exp Hepatol"},{"key":"600_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","volume":"115","author":"DA Simonetto","year":"2020","unstructured":"Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115:18\u201340.","journal-title":"Am J Gastroenterol"},{"issue":"1253\u20131260","key":"600_CR37","first-page":"e1254","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterol. 2012;143(1253\u20131260):e1254.","journal-title":"Gastroenterol"},{"key":"600_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose E, Trebicka J, Mookerjee RP, Angeli P, Gines P. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70:194\u2013202.","journal-title":"J Hepatol"},{"key":"600_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89\u2013118.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1521\u20131530","key":"600_CR40","first-page":"e1528","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(1521\u20131530):e1528.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Current Hepatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-023-00600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11901-023-00600-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-023-00600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T08:46:17Z","timestamp":1685004377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11901-023-00600-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s11901-023-00600-z","relation":{},"ISSN":["2195-9595"],"issn-type":[{"value":"2195-9595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"20 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}